Search

Your search keyword '"Rojas, Juan, I"' showing total 230 results
Start Over Author "Rojas, Juan, I"
230 results on '"Rojas, Juan, I"'

1. Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings

Author

Pestchanker, Claudia, Bertado Cortez, Brenda, Lana Peixoto, Marco A., Gortari, José Ignacio, Castro Suarez, Sheila, Caparo Zamalloa, Cesar, Galiana, Graciana, Peñalver, Francisco, Daccach Marques, Vanesa, Messias, Katharina, Galleguillos, Lorna, García, Fernando, Rojas, Juan I., Patrucco, Liliana, Cristiano, Edgardo, Tkachuk, Verónica, Liwacki, Susana, Correale, Jorge, Marrodan, Mariano, Ysraelit, María C., Vrech, Carlos, Deri, Norma, Leguizamon, Felisa, Tavolini, Darío, Mainella, Carolina, Zanga, Gisela, Alonso Serena, Marina, Ciampi, Ethel, Neto, Herval Ribeiro Soares, Lopez, Pablo, and Carnero Contentti, Edgar

Published
2024
Full Text
View/download PDF

2. The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex

Author

Makhani, Naila, Lebrun-Frenay, Christine, Siva, Aksel, Shabanova, Veronika, Wassmer, Evangeline, Santoro, Jonathan D., Narula, Sona, Brenton, J. Nicholas, Mar, Soe, Durand-Dubief, Francoise, Zephir, Helene, Mathey, Guillaume, Rojas, Juan I., de Seze, Jerome, Tenembaum, Silvia, Stone, Robert Thompson, Casez, Olivier, Carra-Dallière, Clarisse, Neuteboom, Rinze F., Ahsan, Nusrat, Arroyo, Hugo A., Cabre, Philippe, Gombolay, Grace, Inglese, Matilde, Louapre, Celine, Margoni, Monica, Palavra, Filipe, Pohl, Daniela, Reich, Daniel S., Ruet, Aurélie, Thouvenot, Eric, Timby, Niklas, Tintore, Mar, Uygunoglu, Ugur, Vargas, Wendy, Venkateswaran, Sunita, Verhelst, Helene, Wickstrom, Ronny, Azevedo, Christina J., Kantarci, Orhun, Shapiro, Eugene D., Okuda, Darin T., and Pelletier, Daniel

Published
2024
Full Text
View/download PDF

3. Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina

Author

Carnero Contentti, Edgar, López, Pablo A., Pappolla, Agustín, Alonso, Ricardo, Silva, Berenice, Deri, Norma, Balbuena, María E., Burgos, Marcos, Luetic, Geraldine, Alvez Pinheiro, Amelia, Cabrera, Mariela, Hryb, Javier, Nofal, Pedro, Pestchanker, Claudia, Vrech, Carlos, Tavolini, Darío, Tkachuk, Verónica, Zanga, Gisela, Marrodan, Mariano, Ysrraelit, María Célica, Correale, Jorge, Carrá, Adriana, Federico, Belén, Garcea, Orlando, Fernandez Liguori, Nora, Patrucco, Liliana, Cristiano, Edgardo, Giunta, Diego, Alonso Serena, Marina, and Rojas, Juan I.

Published
2024
Full Text
View/download PDF

4. Utility of icobrain for brain volumetry in multiple sclerosis clinical practice

Author

Nguyen, Ai-Lan, Sormani, Maria Pia, Horakova, Dana, Havrdova, Eva H, Barnett, Michael H, De Stefano, Nicola, Battaglini, Marco, Vaneckova, Manuela, Lui, Elaine, Gaillard, Frank, Desmond, Patricia M, Prime, Hayden, Datta, Mineesh, Van der Walt, Anneke, Jokubaitis, Vilija G, Podevyn, Femke, Zivadinov, Robert, Weinstock-Guttman, Bianca, D'hooghe, Marie B, Nagels, Guy, Van Pesch, Vincent, Laureys, Guy, Van Hijfte, Liesbeth, Lechner-Scott, Jeannette, Patti, Francesco, Cristiano, Edgardo, Rojas, Juan I, Sima, Diana M, Van Hecke, Wim, Kalincik, Tomas, and Butzkueven, Helmut

Published
2024
Full Text
View/download PDF

5. Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM)

Author

Carnero Contentti, Edgar, Lopez, Pablo A, Patrucco, Liliana, Cristiano, Edgardo, Miguez, Jimena, Silva, Berenice, Liwacki, Susana, Tkachuk, Verónica, Balbuena, María E, Vrech, Carlos, Deri, Norma, Correale, Jorge, Marrodan, Mariano, Ysrraelit, María C, Fiol, Marcela, Leguizamon, Felisa, Luetic, Geraldine, Tavolini, Darío, Mainella, Carolina, Zanga, Gisela, Burgos, Marcos, Hryb, Javier, Barboza, Andrés, Lazaro, Luciana, Alonso, Ricardo, Fernández Liguori, Nora, Nadur, Débora, Martinez, Alejandra, Steinberg, Judith, Carrá, Adriana, Alonso Serena, Marina, and Rojas, Juan I

Published
2024
Full Text
View/download PDF

6. Treatment strategies and responses for attacks of neuromyelitis optica spectrum disorder: A real-world retrospective cohort study

Author

Carnero Contentti, Edgar, Lopez, Pablo A., Pettinicchi, Juan Pablo, Miguez, Jimena, Patrucco, Liliana, Cristiano, Edgardo, Liwacki, Susana, Tkachuk, Verónica, Balbuena, María E., Vrech, Carlos, Deri, Norma, Correale, Jorge, Marrodan, Mariano, Ysrraelit, María C., Leguizamon, Felisa, Luetic, Geraldine, Tavolini, Darío, Mainella, Carolina, Zanga, Gisela, Burgos, Marcos, Hryb, Javier, Barboza, Andrés, Lazaro, Luciana, Alonso, Ricardo, Fernández Liguori, Nora, Nadur, Débora, Alonso Serena, Marina, Caride, Alejandro, and Rojas, Juan I.

Published
2024
Full Text
View/download PDF

7. Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry

Author

Piedrabuena, Maria A., Correale, Jorge, Fiol, Marcela, Marrodan, Mariano, Rojas, Juan I., Alonso, Marina, Pappolla, Agustín, Miguez, Jimena, Patrucco, Liliana, Cristiano, Edgardo, Vrech, Carlos, Cohen, Leila, Alonso, Ricardo, Silva, Berenice, Luetic, Geraldine, Deri, Norma, Burgos, Marcos, Liwacki, Susana, Piedrabuena, Raul, Tkachuk, Verónica, Barboza, Andres, Martinez, Alejandra, Balbuena, Maria E., Pinheiro, Amelia Alves, Nofal, Pedro, Lopez, Pablo A., Tavolini, Dario, Leguizamon, Felisa, Hryb, Javier P., Tizio, Santiago, Recchia, Luciano, Reich, Edgardo, Contentti, Edgar Carnero, Marcilla, Marcela Parada, Pagani, Fatima, Cabrera, Lorena M., Curbelo, Maria C., Mainella, Carolina, Liguori, Nora Fernández, Coppola, Mariano, Pettinicchi, Juan P., Carra, Adriana, Jose, Gustavo, Nadur, Debora, Bestoso, Santiago, Pestchanker, Claudia, Vazquez, Guido D., Martinez, Carlos M., and Ysrraelit, María C.

Published
2024
Full Text
View/download PDF

10. Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina

Author

Rojas, Juan I., Pappolla, Agustín, Patrucco, Liliana, Cristiano, Edgardo, Miguez, Jimena, Liwacki, Susana, Tkachuk, Verónica, Balbuena, María E., Vrech, Carlos, Deri, Norma, Correale, Jorge, Marrodan, Mariano, Ysrraelit, María C., Fiol, Marcela, Leguizamon, Felisa, Luetic, Geraldine, Menichini, María L., Lopez, Pablo A., Pettinicchi, Juan Pablo, Criniti, Juan, Caride, Alejandro, Tavolini, Darío, Mainella, Carolina, Zanga, Gisela, Burgos, Marcos, Hryb, Javier, Barboza, Andrés, Lazaro, Luciana, Alonso, Ricardo, Silva, Berenice, Fernández Liguori, Nora, Nadur, Débora, Chercoff, Aníbal, Martinez, Alejandra, Steinberg, Judith, Garcea, Orlando, Carrá, Adriana, Alonso Serena, Marina, and Carnero Contentti, Edgar

Published
2023
Full Text
View/download PDF

11. Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs

Author

Silva, Berenice A., Carnero Contentti, Edgar, Becker, Jefferson, Carranza, José I, Correa-Díaz, Patricio E, Galleguillos Goiry, Lorna, Garcea, Orlando, Gracia, Fernando, Hamuy, Fernando, Macías, Miguel Angel, Navas, Carlos, Nuñez, Sebastián, Rojas, Juan I, Farez, Mauricio F., Alonso, Ricardo, and López, Pablo

Published
2023
Full Text
View/download PDF

15. Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM

Author

Rojas, Juan I., Luetic, Geraldine G., Vrech, Carlos, Pappolla, Agustín, Patrucco, Liliana, Cristiano, Edgardo, Marrodan, Mariano, Ysrraelit, María C., Fiol, Marcela, Correale, Jorge, Cohen, Leila, Alonso, Ricardo, Silva, Berenice, Casas, Magdalena, Garcea, Orlando, Deri, Norma, Burgos, Marcos, Liwacki, Susana, Tkachuk, Verónica, Barboza, Andres, Piedrabuena, Raúl, Blaya, Patricio, Steinberg, Judith, Martínez, Alejandra, Carra, Adriana, Tavolini, Darío, López, Pablo, Knorre, Eduardo, Nofal, Pedro, Carnero Contentti, Edgar, Alves Pinheiro, Amelia, Leguizamon, Felisa, Silva, Emanuel, Hryb, Javier, Balbuena, María Eugenia, Zanga, Gisela, Kohler, Matías, Lazaro, Luciana, Tizio, Santiago, Mainella, Carolina, Blanche, Jorge, Parada Marcilla, Marcela, Fracaro, María Eugenia, Menichini, María Laura, Sgrilli, Gustavo, Divi, Pablo, Jacobo, Miguel, Cabrera, Mariela, Míguez, Jimena, Fernandez Liguori, Nora, Viglione, Juan Pablo, Nadur, Debora, Alonso Serena, Marina, and Nuñez, Sebastián

Published
2022
Full Text
View/download PDF

17. Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM

Author

Rojas, Juan I., Pappolla, Agustín, Blaya, Patricio, Marrodán, Mariano, Ysrraelit, María C., Luetic, Geraldine, Liwacki, Susana, Barboza, Andrés, Burgos, Marcos, Cohen, Leila, Mainella, Carolina, Zanga, Gisela, Menichini, María L., Tavolini, Dario, Tkachuk, Verónica, Lopez, Pablo, Lequizamon, Felisa, Knorre, Eduardo, Nofal, Pedro, Patrucco, Liliana, Miguez, Jimena, Cristiano, Edgardo, Fiol, Marcela, Correale, Jorge, Gaitán, María I., Alonso, Ricardo, Silva, Berenice, Garcea, Orlando, Carrá, Adriana, Fernandez Liguori, Nora, Alonso Serena, Marina, and Carnero Contentti, Edgar

Published
2022
Full Text
View/download PDF

18. Guía de práctica clínica: tratamiento sintomático de esclerosis múltiple. Grupo de Trabajo de Enfermedades Desmielinizantes. Sociedad Neurológica Argentina

Author

Barboza, Andrés G., Sinay, Vladimiro, Zanga, Gisela, Alonso, Ricardo, Silva, Berenice, Saladino, María Laura, Cohen, Leila, Luetic, Geraldine G., Camerlingo, Sebastián, Ysrraelit, María Célica, Tenembaun, Silvia N., Tarulla, Adriana, Carnero Contentti, Edgar, López, Pablo A., Pita, Cecilia, Tavolini, Darío, Steinberg, Judith, Menichini, María Laura, Rojas, Juan I., Tizio, Santiago, Tkachuk, Verónica, González, Fernando Adrián, Martínez, Alejandra, Laffue, Alfredo, Pagani Cassara, Fátima, Piedrabuena, Raúl, Pérez, Celia, Fernández Liguori, Nora, Eizaguirre, María Bárbara, Patrucco, Liliana, Deri, Norma Haydee, Hryb, Javier, and Mellinger, Surai

Published
2022
Full Text
View/download PDF

19. The real‐world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody‐associated disease criteria in a Latin American cohort.

Author

Carnero Contentti, Edgar, Pestchanker, Claudia, Ciampi, Ethel, Castro Suarez, Sheila, Caparo Zamalloa, Cesar, Daccach Marques, Vanesa, Messias, Katharina, Gortari, José Ignacio, Tkachuk, Verónica, Silva, Berenice, Mainella, Carolina, Reyes, Saúl, Toro, Jaime, Rodriguez, Juan, Correa‐Diaz, Edgar, Rojas, Juan I., and Paul, Friedemann

Subjects
MYELIN oligodendrocyte glycoprotein, TRANSVERSE myelitis, OPTIC neuritis, ANTIBODY titer, DISEASE duration
Abstract

Background and Purpose: The diagnostic criteria for myelin oligodendrocyte glycoprotein antibody (MOG‐IgG)‐associated disease (MOGAD) were published in 2023. We aimed to determine the performance of the new criteria in Latin American (LATAM) patients compared with the 2018 criteria and explore the significance of MOG–IgG titers in diagnosis. Methods: We retrospectively reviewed the medical records of LATAM (Argentina, Chile, Brazil, Peru, Ecuador, and Colombia) adult patients with one clinical MOGAD event and MOG‐IgG positivity confirmed by cell‐based assay. Both 2018 and 2023 MOGAD criteria were applied, calculating diagnostic performance indicators. Results: Among 171 patients (predominantly females, mean age at first attack = 34.1 years, mean disease duration = 4.5 years), 98.2% patients met the 2018 criteria, and of those who did not fulfill diagnostic criteria (n = 3), all tested positive for MOG‐IgG (one low‐positive and two without reported titer). Additionally, 144 (84.2%) patients met the 2023 criteria, of whom 57 (39.5%) had MOG‐IgG+ titer information (19 clearly positive and 38 low‐positive), whereas 87 (60.5%) patients had no MOG‐IgG titer. All 144 patients met diagnostic supporting criteria. The remaining 27 patients did not meet the 2023 MOGAD criteria due to low MOG‐IgG (n = 12) or lack of titer antibody access (n = 15), associated with the absence of supporting criteria. The 2023 MOGAD criteria showed a sensitivity of 86% (95% confidence interval = 0.80–0.91) and specificity of 100% compared to the 2018 criteria. Conclusions: These findings support the diagnostic utility of the 2023 MOGAD criteria in an LATAM cohort in real‐world practice, despite limited access to MOG‐IgG titration. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis.

Author

Marrodan, Mariano, Calandri, Ismael L., Bocancea, Diana I., Ysrraelit, Maria C., Gomez Figueroa, Enrique, Massó Páez, Montserrat, Flores, José D.J., Rojas, Juan I., Ciampi, Ethel, Ioli, Pablo, Zanga, Gisela, Ardohain, Carolina, Fracaro, Maria E., Amaya, Mariela, Tkachuk, Verónica, Fernandez, Victoria C., José, Gustavo, Silva, Emanuel, Luetic, Geraldine, and Carnero Contentti, Edgar

Subjects
CENTRAL nervous system, CORPUS callosum, DISABILITIES, MULTIPLE sclerosis, VASCULITIS
Abstract

Objective: Susac syndrome (SuS), multiple sclerosis (MS), and primary angiitis of the central nervous system (PACNS) present diagnostic challenges due to overlapping clinical features. We aimed to enhance diagnostic precision by developing the SPAMS (SuS, PACNS, MS) score, a practical radiological tool. Methods: This multicenter study included 99 patients (43 SuS, 37 MS, 19 PACNS) from South American countries. Relevant MRI features were identified through an elastic‐net model determined key variables. Results: The SPAMS score assigned 2 points for snowball lesions, 1 point for spokes‐like lesions, or if there are more than 4 lesions in the corpus callosum, corpus callosum involvement, or cerebellar involvement. It subtracted 1 point if gadolinium‐enhancing lesions or 4 points if Dawson's fingers are present. Bootstrapping validated the optimal cutoff at 2 points, exhibiting a diagnostic performance of area under the curve = 0.931, sensitivity = 88%, specificity = 89%, positive predictive value = 88%, negative predictive value = 89%, and accuracy = 88%. Interpretation: When specific MRI findings coexisted, the SPAMS score differentiated SuS from MS and PACNS. Access to MRI and standard protocol sequences makes it a valuable tool for timely diagnosis and treatment, potentially preventing disability progression and severe clinical outcomes. ANN NEUROL 2024;96:846–854 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Aggressive multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM

Author

Kohler, Matías, Kohler, Eduardo, Vrech, Carlos, Pappolla, Agustín, Miguez, Jimena, Patrucco, Liliana, Correale, Jorge, Marrodan, Mariano, Gaitán, María I., Fiol, Marcela, Negrotto, Laura, Ysrraelit, María C., Cristiano, Edgardo, Carrá, Adriana, Steinberg, Judith, Martinez, Alejandra D., Curbelo, María C., Cohen, Leila, Alonso, Ricardo, Garcea, Orlando, Pita, Cecilia, Silva, Berenice, Luetic, Geraldine, Deri, Norma, Balbuena, Maria E., Tkachuk, Verónica, Carnero Contentti, Edgar, Lopez, Pablo A., Pettinicchi, Juan P., Caride, Alejandro, Burgos, Marcos, Leguizamon, Felisa, Knorre, Eduardo, Piedrabuena, Raúl, Barboza, Andrés, Liwacki, Susana, Nofal, Pedro, Volman, Gabriel, Alvez Pinheiro, Amelia, Hryb, Javier, Tavolini, Dario, Blaya, Patricio, Recchia, Luciano, Mainella, Carolina, Silva, Emanuel, Blanche, Jorge, Tizio, Santiago, Saladino, Maria L., Caceres, Fernando, Fernandez Liguori, Nora, Lazaro, Luciana, Zanga, Gisela, Parada Marcilla, Marcela, Fracaro, Maria E., Pagani Cassara, Fatima, Vazquez, Guido, Sinay, Vladimiro, Sgrilli, Gustavo, Divi, Pablo, Jacobo, Miguel, Reich, Edgardo, Cabrera, Lorena M., Menichini, María L., Coppola, Mariano, Martos, Ivan, Viglione, Juan P., Jose, Gustavo, Bestoso, Santiago, Manzi, Ruben, Giunta, Diego, Doldan, Maria.L., Alonso Serena, Marina, and Rojas, Juan I.

Published
2021
Full Text
View/download PDF

24. Guías de práctica para indicación y contraindicaciones de vacunación de pacientes con esclerosis múltiple

Author

Barboza, Andrés G., Sinay, Vladimiro, Silva, Berenice Anabel, Rojas, Juan I., Ysrraelit, María Célica, Carnero Contentti, Edgar, Negrotto, Laura, Tavolini, Darío, Deri, Norma, Tizio, Santiago, Gaitán, María Inés, Luetic, Geraldine, Patrucco, Liliana, Martínez, Alejandra D., Parada Marcilla, Marcela, Hryb, Javier, Alonso, Ricardo, Bestoso, Santiago, Cabrera, Lorena M., Cristiano, Edgardo, Jacobo, Miguel, Liwacki, Susana, Lopez, Pablo A., Mainella, Carolina, Menichini, María Laura, Miguez, Jimena, Pagani Cassara, Fatima, Pérez, Celia, Piedrabuena, Raúl, Rotta Escalante, Roberto, Steinberg, Judith, Tkachuk, Veronica Analia, Alejandro Vrech, Carlos, and Zanga, Gisela

Published
2021
Full Text
View/download PDF

25. Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Author

Simpson-Yap, Steve, Pirmani, Ashkan, Kalincik, Tomas, De Brouwer, Edward, Geys, Lotte, Parciak, Tina, Helme, Anne, Rijke, Nick, Hillert, Jan A., Moreau, Yves, Edan, Gilles, Sharmin, Sifat, Spelman, Tim, McBurney, Robert, Schmidt, Hollie, Bergmann, Arnfin B., Braune, Stefan, Stahmann, Alexander, Middleton, Rod M., Salter, Amber, Bebo, Bruce, Van der Walt, Anneke, Butzkueven, Helmut, Ozakbas, Serkan, Boz, Cavit, Karabudak, Rana, Alroughani, Raed, Rojas, Juan I., van der Mei, Ingrid A., Sciascia do Olival, Guilherme, Magyari, Melinda, Alonso, Ricardo N., Nicholas, Richard S., Chertcoff, Anibal S., de Torres, Ana Zabalza, Arrambide, Georgina, Nag, Nupur, Descamps, Annabel, Costers, Lars, Dobson, Ruth, Miller, Aleisha, Rodrigues, Paulo, Prčkovska, Vesna, Comi, Giancarlo, and Peeters, Liesbet M.

Published
2022
Full Text
View/download PDF

26. Smoking and Health-Related Quality of Life in Patients With Multiple Sclerosis From Latin America.

Author

Carnero Contentti, Edgar, Rojas, Juan I., Giachello, Susana, Henestroza, Paula, and Lopez, Pablo A.

Abstract

BACKGROUND: Tobacco smoking is an important, modifiable, environmental risk factor for multiple sclerosis (MS) with a relevant impact on health-related quality of life (HRQOL). We aimed to assess the use of tobacco in individuals with MS from Latin America (LATAM), and its impact on HRQOL. METHODS: We conducted a cross-sectional study based on a LATAM web-based survey. Demographics, social and clinical data, information on physical disability, and HRQOL scores were collected using the MS Impact Scale-29 (MSIS-29), the Fatigue Severity Scale (FSS), and the Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Individuals with MS were classified at the time of the survey as follows: never-smokers (ie, patients who reported they had never smoked), past smokers (those who had smoked tobacco but not during the past year), or current smokers. For the analysis, groups were compared. RESULTS: 425 patients (74.6% female) from 17 LATAM countries were included, mean age 43.6 ± 11 years and median Expanded Disability Status Scale score 2. There were 122 (28.7%) current smokers, 178 (41.9%) past smokers, and 125 (30.4%) never-smokers. Current smokers had significantly higher MSIS-29 physical (physical worsening), FSS (fatigue), and HADS-A (anxiety) scores compared with past and never-smokers after being adjusted for covariables. No significant differences were observed in any of the other analyzed demographic, clinical, and therapeutic variables. Thirty percent of the current and past smokers groups had never had their neurologists discuss smoking cessation with them. CONCLUSIONS: Individuals with MS who were current smokers had higher fatigue and anxiety scores and worse HRQOL compared with past and never-smokers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Author

Simpson-Yap, Steve, De Brouwer, Edward, Kalincik, Tomas, Rijke, Nick, Hillert, Jan A, Walton, Clare, Edan, Gilles, Moreau, Yves, Spelman, Tim, Geys, Lotte, Parciak, Tina, Gautrais, Clement, Lazovski, Nikola, Pirmani, Ashkan, Ardeshirdavanai, Amin, Forsberg, Lars, Glaser, Anna, McBurney, Robert, Schmidt, Hollie, Bergmann, Arnfin B, Braune, Stefan, Stahmann, Alexander, Middleton, Rodden, Salter, Amber, Fox, Robert J., van der Walt, Anneke, Butzkueven, Helmut, Alroughani, Raed, Ozakbas, Serkan, Rojas, Juan I, van der Mei, Ingrid, Nag, Nupur, Ivanov, Rumen, Sciascia do Olival, Guilherme, Dias, Alice Estavo, Magyari, Melinda, Brum, Doralina, Mendes, Maria Fernanda, Alonso, Ricardo N, Nicholas, Richard S, Bauer, Johana, Chertcoff, Aníbal Sebastián, Zabalza, Anna, Arrambide, Georgina, Fidao, Alex, Comi, Giancarlo, and Peeters, Liesbet

Published
2021
Full Text
View/download PDF

28. Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force

Author

Parciak, Tina, primary, Geys, Lotte, additional, Helme, Anne, additional, van der Mei, Ingrid, additional, Hillert, Jan, additional, Schmidt, Hollie, additional, Salter, Amber, additional, Zakaria, Magd, additional, Middleton, Rodden, additional, Stahmann, Alexander, additional, Dobay, Pamela, additional, Hernandez Martinez-Lapiscina, Elena, additional, Iaffaldano, Pietro, additional, Plueschke, Kelly, additional, Rojas, Juan I, additional, Sabidó, Meritxell, additional, Magyari, Melinda, additional, van der Walt, Anneke, additional, Arickx, Francis, additional, Comi, Giancarlo, additional, and Peeters, Liesbet M, additional

Published
2023
Full Text
View/download PDF

29. Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: A study from the RelevarEM registry

Author

Carnero Contentti, Edgar, primary, Lopez, Pablo A, additional, Pettinicchi, Juan Pablo, additional, Criniti, Juan, additional, Pappolla, Agustín, additional, Miguez, Jimena, additional, Cristiano, Edgardo, additional, Patrucco, Liliana, additional, Liwacki, Susana, additional, Tkachuk, Verónica, additional, Balbuena, María E, additional, Vrech, Carlos, additional, Deri, Norma, additional, Correale, Jorge, additional, Marrodan, Mariano, additional, Ysrraelit, María C, additional, Leguizamon, Felisa, additional, Luetic, Geraldine, additional, Menichini, María L, additional, Tavolini, Darío, additional, Mainella, Carolina, additional, Zanga, Gisela, additional, Burgos, Marcos, additional, Hryb, Javier, additional, Barboza, Andrés, additional, Lazaro, Luciana, additional, Alonso, Ricardo, additional, Fernández Liguori, Nora, additional, Nadur, Débora, additional, Alonso Serena, Marina, additional, Caride, Alejandro, additional, Paul, Friedemann, additional, and Rojas, Juan I, additional

Published
2023
Full Text
View/download PDF

31. Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.

Author

Camerlingo, Sebastian, Rubinstein, Fernando, Celia Ysrraelit, Maria, Correale, Jorge, Carnero Contentti, Edgar, Rojas, Juan I, Patrucco, Liliana, Leguizamon, Felisa del Valle, Tkachuk, Veronica, Fernandez Liguori, Nora, Cristiano, Edgardo, Mainella, Carolina, Zanga, Gisela, Carra, Adriana, Marrodan, Mariano, Martinez, Alejandra Diana, Silva, Berenice Anabel, and Alonso, Ricardo

Subjects
AGE factors in disease, SEX factors in disease, MULTIPLE sclerosis, AGE of onset, GENDER
Abstract

Background and Objectives: Primary-progressive multiple sclerosis (PPMS) is characterized by gradual neurological deterioration without relapses. This study aimed to investigate the clinical impact of gender and age at disease onset on disease progression and disability accumulation in patients with this disease phenotype. Methods: Secondary data from the RelevarEM registry, a longitudinal database in Argentina, were analyzed. The cohort comprised patients with PPMS who met inclusion criteria. Statistical analysis with multilevel Bayesian robust regression modeling was conducted to assess the associations between gender, age at onset, and Expanded Disability Status Scale (EDSS) score trajectories. Results: We identified 125 patients with a confirmed diagnosis of PPMS encompassing a total of 464 observations. We found no significant differences in EDSS scores after 10 years of disease progression between genders (−0.08; credible interval (CI): −0.60, 0.42). A 20-year difference in age at onset did not show significant differences in EDSS score after 10 years of disease progression (0.281; CI: −0.251, 0.814). Finally, we also did not find any clinically relevant difference between gender EDSS score with a difference of 20 years in age at onset (−0.021; CI: −0.371, 0.319). Conclusion: Biological plausibility of gender and age effects does not correlate with clinical impact measured by EDSS score. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force.

Author

Parciak, Tina, Geys, Lotte, Helme, Anne, van der Mei, Ingrid, Hillert, Jan, Schmidt, Hollie, Salter, Amber, Zakaria, Magd, Middleton, Rodden, Stahmann, Alexander, Dobay, Pamela, Hernandez Martinez-Lapiscina, Elena, Iaffaldano, Pietro, Plueschke, Kelly, Rojas, Juan I, Sabidó, Meritxell, Magyari, Melinda, van der Walt, Anneke, Arickx, Francis, and Comi, Giancarlo

Subjects
TASK forces, MULTIPLE sclerosis, MAGNETIC resonance imaging, DATA dictionaries
Abstract

Background: As of September 2022, there was no globally recommended set of core data elements for use in multiple sclerosis (MS) healthcare and research. As a result, data harmonisation across observational data sources and scientific collaboration is limited. Objectives: To define and agree upon a core dataset for real-world data (RWD) in MS from observational registries and cohorts. Methods: A three-phase process approach was conducted combining a landscaping exercise with dedicated discussions within a global multi-stakeholder task force consisting of 20 experts in the field of MS and its RWD to define the Core Dataset. Results: A core dataset for MS consisting of 44 variables in eight categories was translated into a data dictionary that has been published and disseminated for emerging and existing registries and cohorts to use. Categories include variables on demographics and comorbidities (patient-specific data), disease history, disease status, relapses, magnetic resonance imaging (MRI) and treatment data (disease-specific data). Conclusion: The MS Data Alliance Core Dataset guides emerging registries in their dataset definitions and speeds up and supports harmonisation across registries and initiatives. The straight-forward, time-efficient process using a dedicated global multi-stakeholder task force has proven to be effective to define a concise core dataset. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

Author

Simpson-Yap, Steve, primary, Pirmani, Ashkan, additional, De Brouwer, Edward, additional, Peeters, Liesbet M., additional, Geys, Lotte, additional, Parciak, Tina, additional, Helme, Anne, additional, Hillert, Jan, additional, Moreau, Yves, additional, Edan, Gilles, additional, Spelman, Tim, additional, Sharmin, Sifat, additional, McBurney, Robert, additional, Schmidt, Hollie, additional, Bergmann, Arnfin, additional, Braune, Stefan, additional, Stahmann, Alexander, additional, Middleton, Rodden, additional, Salter, Amber, additional, Bebo, Bruce, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Ozakbas, Serkan, additional, Karabudak, Rana, additional, Boz, Cavit, additional, Alroughani, Raed, additional, Rojas, Juan I, additional, van der Mei, Ingrid, additional, Sciascia do Olival, Guilherme, additional, Magyari, Melinda, additional, Alonso, Ricardo, additional, Nicholas, Richard, additional, Chertcoff, Anibal, additional, Zabalza, Ana, additional, Arrambide, Georgina, additional, Nag, Nupur, additional, Descamps, Annabel, additional, Costers, Lars, additional, Dobson, Ruth, additional, Miller, Aleisha, additional, Rodrigues, Paulo, additional, Prčkovska, Vesna, additional, Comi, Giancarlo, additional, and Kalincik, Tomas, additional

Published
2022
Full Text
View/download PDF

34. Updated Results of the COVID-19 in MS Global Data Sharing Initiative

Author

Simpson-Yap, Steve, PIRMANI, Ashkan, Kalincik, Tomas, DE BROUWER, Edward, GEYS, Lotte, PARCIAK, Tina, Helme, Anne, Rijke, Nick, Hillert, Jan A., Moreau, Yves, Edan, Gilles, Sharmin, Sifat, Spelman, Tim, McBurney, Robert, Schmidt, Hollie, Bergmann, Arnfin B., Braune, Stefan, Stahmann, Alexander, Middleton, Rod M., Salter, Amber, Bebo, Bruce, Van der Walt, Anneke, Butzkueven, Helmut, Ozakbas, Serkan, Boz, Cavit, Karabudak, Rana, Alroughani, Raed, Rojas, Juan I., van der Mei, Ingrid A., Sciascia do Olival, Guilherme, Magyari, Melinda, Alonso, Ricardo N., Nicholas, Richard S., Chertcoff, Anibal S., de Torres, Ana Zabalza, Arrambide, Georgina, Nag, Nupur, Descamps, Annabel, Costers, Lars, Dobson, Ruth, Miller, Aleisha, Rodrigues, Paulo, Prčkovska, Vesna, Comi, Giancarlo, PEETERS, Liesbet, Simpson-Yap, Steve, PIRMANI, Ashkan, Kalincik, Tomas, DE BROUWER, Edward, GEYS, Lotte, PARCIAK, Tina, Helme, Anne, Rijke, Nick, Hillert, Jan A., Moreau, Yves, Edan, Gilles, Sharmin, Sifat, Spelman, Tim, McBurney, Robert, Schmidt, Hollie, Bergmann, Arnfin B., Braune, Stefan, Stahmann, Alexander, Middleton, Rod M., Salter, Amber, Bebo, Bruce, Van der Walt, Anneke, Butzkueven, Helmut, Ozakbas, Serkan, Boz, Cavit, Karabudak, Rana, Alroughani, Raed, Rojas, Juan I., van der Mei, Ingrid A., Sciascia do Olival, Guilherme, Magyari, Melinda, Alonso, Ricardo N., Nicholas, Richard S., Chertcoff, Anibal S., de Torres, Ana Zabalza, Arrambide, Georgina, Nag, Nupur, Descamps, Annabel, Costers, Lars, Dobson, Ruth, Miller, Aleisha, Rodrigues, Paulo, Prčkovska, Vesna, Comi, Giancarlo, and PEETERS, Liesbet

Subjects
Male, Multiple Sclerosis, Information Dissemination, Risk Factors, Natalizumab, Humans, COVID-19, Glatiramer Acetate, Multiple Sclerosis, Chronic Progressive, Antigens, CD20, Rituximab, Immunosuppressive Agents
Abstract

Background and Objectives Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed. Methods Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19). COVID-19 severity outcomes (hospitalization, admission to intensive care unit [ICU], requiring artificial ventilation, and death) were assessed using multilevel mixed-effects ordered probit and logistic regression, adjusted for age, sex, disability, and MS phenotype. DMTs were individually compared with glatiramer acetate, and anti-CD20 DMTs with pooled other DMTs and with natalizumab. Results Of 5,648 patients, 922 (16.6%) with suspected and 4,646 (83.4%) with confirmed COVID-19 were included. Male sex, older age, progressive MS, and higher disability were associated with more severe COVID-19. Compared with glatiramer acetate, ocrelizumab and rituximab were associated with higher probabilities of hospitalization (4% [95% CI 1–7] and 7% [95%CI 4–11]), ICU/artificial ventilation (2% [95% CI 0–4] and 4% [95% CI 2–6]), and death (1% [95% CI 0–2] and 2% [95% CI 1–4]) (predicted marginal effects). Untreated patients had 5% (95%CI2–8),3%(95%CI1–5),and1%(95%CI0–3)higherprobabilitiesofthe3respectivelevels of COVID-19 severity than glatiramer acetate. Compared with pooled other DMTs and with natalizumab, the associations of ocrelizumab and rituximab with COVID-19 severity were also more pronounced. All associations persisted/enhanced on restriction to confirmed COVID-19. Discussion Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that the use of anti-CD20 medication (both ocrelizumab and rituximab), as well as male sex, older age, progressive MS, and higher disability are associated with more severe course of COVID-19. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the operational costs linked to this study are funded by the Multiple Sclerosis International Federation (MSIF) and the Multiple Sclerosis Data Alliance (MSDA), acting under the umbrella of the European Charcot Foundation (ECF). The MSDA receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Canopy Growth Corporation, Genzyme, Icometrix, Merck, Mylan, Novartis, QMENTA, Quanterix, and Roche. MSIF receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Genzyme, Med-Day, Merck, Mylan, Novartis, and Roche. This work was supported by the Flemish Government under the Onderzoeksprogramma Artifici¨ele Intelligentie (AI) Vlaanderen programme and the Research Foundation Fladers (FWO) for ELIXIR Belgium— Flanders (FWO) for ELIXIR Belgium. The central platform was provided by QMENTA, and the computational resources used in this work were provided by Amazon. The statistical analysis was carried out at CORe, The University of Melbourne, with support from NHMRC (1129189 and 1140766). Acknowledgment The authors thank the patients comprising the studies and registries that are part of this project, and the authors hope that the results of this work may be of benefit to them and patients like them.

Published
2022

35. MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease.

Author

Carnero Contentti, Edgar, Okuda, Darin T., Rojas, Juan I., Chien, Claudia, Paul, Friedemman, and Alonso, Ricardo

Subjects
NEUROMYELITIS optica, MYELIN oligodendrocyte glycoprotein, MULTIPLE sclerosis, CENTRAL nervous system diseases, MAGNETIC resonance imaging, OPTIC nerve
Abstract

Differentiating multiple sclerosis (MS) from other relapsing inflammatory autoimmune diseases of the central nervous system such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) is crucial in clinical practice. The differential diagnosis may be challenging but making the correct ultimate diagnosis is critical, since prognosis and treatments differ, and inappropriate therapy may promote disability. In the last two decades, significant advances have been made in MS, NMOSD, and MOGAD including new diagnostic criteria with better characterization of typical clinical symptoms and suggestive imaging (magnetic resonance imaging [MRI]) lesions. MRI is invaluable in making the ultimate diagnosis. An increasing amount of new evidence with respect to the specificity of observed lesions as well as the associated dynamic changes in the acute and follow‐up phase in each condition has been reported in distinct studies recently published. Additionally, differences in brain (including the optic nerve) and spinal cord lesion patterns between MS, aquaporin4‐antibody‐positive NMOSD, and MOGAD have been described. We therefore present a narrative review on the most relevant findings in brain, spinal cord, and optic nerve lesions on conventional MRI for distinguishing adult patients with MS from NMOSD and MOGAD in clinical practice. In this context, cortical and central vein sign lesions, brain and spinal cord lesions characteristic of MS, NMOSD, and MOGAD, optic nerve involvement, role of MRI at follow‐up, and new proposed diagnostic criteria to differentiate MS from NMOSD and MOGAD were discussed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina

Author

Rojas, Juan I., primary, Pappolla, Agustín, additional, Patrucco, Liliana, additional, Cristiano, Edgardo, additional, Miguez, Jimena, additional, Liwacki, Susana, additional, Tkachuk, Verónica, additional, Balbuena, María E., additional, Vrech, Carlos, additional, Deri, Norma, additional, Correale, Jorge, additional, Marrodan, Mariano, additional, Ysrraelit, María C., additional, Fiol, Marcela, additional, Leguizamon, Felisa, additional, Luetic, Geraldine, additional, Menichini, María L., additional, Lopez, Pablo A., additional, Pettinicchi, Juan Pablo, additional, Criniti, Juan, additional, Caride, Alejandro, additional, Tavolini, Darío, additional, Mainella, Carolina, additional, Zanga, Gisela, additional, Burgos, Marcos, additional, Hryb, Javier, additional, Barboza, Andrés, additional, Lazaro, Luciana, additional, Alonso, Ricardo, additional, Silva, Berenice, additional, Fernández Liguori, Nora, additional, Nadur, Débora, additional, Chercoff, Aníbal, additional, Martinez, Alejandra, additional, Steinberg, Judith, additional, Garcea, Orlando, additional, Carrá, Adriana, additional, Alonso Serena, Marina, additional, and Carnero Contentti, Edgar, additional

Published
2022
Full Text
View/download PDF

37. 2233 Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 DMTs deleterious for COVID-19 severity but interferons not protective among people with MS

Author

Simpson-Yap, Steve, primary, Pirmani, Ashkan, additional, Kalincik, Tomas, additional, Brouwer, Edward De, additional, Geys, Lotte, additional, Parciak, Tina, additional, Helme, Anne, additional, Rijke, Nick, additional, Hillert, Jan, additional, Moreau, Yves, additional, Edan, Gilles, additional, Spelman, Tim, additional, Sharmin, Sifat, additional, McBurney, Robert, additional, Schmidt, Hollie, additional, Bergmann, Arnfin, additional, Braune, Stefan, additional, Stahmann, Alexander, additional, Salter, Amber, additional, Bebo, Bruce, additional, Walt, Anneke Van der, additional, Butzkueven, Helmut, additional, Ozakbas, Serkan, additional, Karabudak, Rana, additional, Alroughani, Raed, additional, Rojas, Juan I, additional, Mei, Ingrid Van Der, additional, Olival, Guilherme Sciascia do, additional, Magyari, Melinda, additional, Alonso, Ricardo, additional, Nicholas, Richard, additional, Chertcoff, Anibal, additional, Zabalza, Ana, additional, Arrambide, Georgina, additional, Nag, Nupur, additional, Descamps, Annabel, additional, Costers, Lars, additional, Dobson, Ruth, additional, Miller, Aleisha, additional, Rodriguez, Paolo, additional, Prchkovska, Vesna, additional, Comi, Giancarlo, additional, and Peeters, Liesbet, additional

Published
2022
Full Text
View/download PDF

39. Updated Results of the COVID-19 in MS Global Data Sharing Initiative:Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Author

Simpson-Yap, Steve, Pirmani, Ashkan, Kalincik, Tomas, De Brouwer, Edward, Geys, Lotte, Parciak, Tina, Helme, Anne, Rijke, Nick, Hillert, Jan A., Moreau, Yves, Edan, Gilles, Sharmin, Sifat, Spelman, Tim, McBurney, Robert, Schmidt, Hollie, Bergmann, Arnfin B., Braune, Stefan, Stahmann, Alexander, Middleton, Rod M., Salter, Amber, Bebo, Bruce, Van der Walt, Anneke, Butzkueven, Helmut, Ozakbas, Serkan, Boz, Cavit, Karabudak, Rana, Alroughani, Raed, Rojas, Juan I., van der Mei, Ingrid A., Sciascia do Olival, Guilherme, Magyari, Melinda, Alonso, Ricardo N., Nicholas, Richard S., Chertcoff, Anibal S., de Torres, Ana Zabalza, Arrambide, Georgina, Nag, Nupur, Descamps, Annabel, Costers, Lars, Dobson, Ruth, Miller, Aleisha, Rodrigues, Paulo, Prčkovska, Vesna, Comi, Giancarlo, Peeters, Liesbet M., Simpson-Yap, Steve, Pirmani, Ashkan, Kalincik, Tomas, De Brouwer, Edward, Geys, Lotte, Parciak, Tina, Helme, Anne, Rijke, Nick, Hillert, Jan A., Moreau, Yves, Edan, Gilles, Sharmin, Sifat, Spelman, Tim, McBurney, Robert, Schmidt, Hollie, Bergmann, Arnfin B., Braune, Stefan, Stahmann, Alexander, Middleton, Rod M., Salter, Amber, Bebo, Bruce, Van der Walt, Anneke, Butzkueven, Helmut, Ozakbas, Serkan, Boz, Cavit, Karabudak, Rana, Alroughani, Raed, Rojas, Juan I., van der Mei, Ingrid A., Sciascia do Olival, Guilherme, Magyari, Melinda, Alonso, Ricardo N., Nicholas, Richard S., Chertcoff, Anibal S., de Torres, Ana Zabalza, Arrambide, Georgina, Nag, Nupur, Descamps, Annabel, Costers, Lars, Dobson, Ruth, Miller, Aleisha, Rodrigues, Paulo, Prčkovska, Vesna, Comi, Giancarlo, and Peeters, Liesbet M.

Abstract

Background and Objectives Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed. Methods Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19). COVID-19 severity outcomes (hospitalization, admission to intensive care unit [ICU], requiring artificial ventilation, and death) were assessed using multilevel mixed-effects ordered probit and logistic regression, adjusted for age, sex, disability, and MS phenotype. DMTs were individually compared with glatiramer acetate, and anti-CD20 DMTs with pooled other DMTs and with natalizumab. Results Of 5,648 patients, 922 (16.6%) with suspected and 4,646 (83.4%) with confirmed COVID-19 were included. Male sex, older age, progressive MS, and higher disability were associated with more severe COVID-19. Compared with glatiramer acetate, ocrelizumab and rituximab were associated with higher probabilities of hospitalization (4% [95% CI 1–7] and 7% [95% CI 4–11]), ICU/artificial ventilation (2% [95% CI 0–4] and 4% [95% CI 2–6]), and death (1% [95% CI 0–2] and 2% [95% CI 1–4]) (predicted marginal effects). Untreated patients had 5% (95% CI 2–8), 3% (95% CI 1–5), and 1% (95% CI 0–3) higher probabilities of the 3 respective levels of COVID-19 severity than glatiramer acetate. Compared with pooled other DMTs and with natalizumab, the associations of ocrelizumab and rituximab with COVID-19 severity were also more pronounced. All associations persisted/enhanced on restriction to confirmed COVID-19. Discussion Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that, BACKGROUND AND OBJECTIVES: Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed. METHODS: Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19). COVID-19 severity outcomes (hospitalization, admission to intensive care unit [ICU], requiring artificial ventilation, and death) were assessed using multilevel mixed-effects ordered probit and logistic regression, adjusted for age, sex, disability, and MS phenotype. DMTs were individually compared with glatiramer acetate, and anti-CD20 DMTs with pooled other DMTs and with natalizumab. RESULTS: Of 5,648 patients, 922 (16.6%) with suspected and 4,646 (83.4%) with confirmed COVID-19 were included. Male sex, older age, progressive MS, and higher disability were associated with more severe COVID-19. Compared with glatiramer acetate, ocrelizumab and rituximab were associated with higher probabilities of hospitalization (4% [95% CI 1-7] and 7% [95% CI 4-11]), ICU/artificial ventilation (2% [95% CI 0-4] and 4% [95% CI 2-6]), and death (1% [95% CI 0-2] and 2% [95% CI 1-4]) (predicted marginal effects). Untreated patients had 5% (95% CI 2-8), 3% (95% CI 1-5), and 1% (95% CI 0-3) higher probabilities of the 3 respective levels of COVID-19 severity than glatiramer acetate. Compared with pooled other DMTs and with natalizumab, the associations of ocrelizumab and rituximab with COVID-19 severity were also more pronounced. All associations persisted/enhanced on restriction to confirmed COVID-19. DISCUSSION: Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that the use of anti-CD2

Published
2022

40. SEROLOGICAL RESPONSE TO SARS-COV-2 VACCINES IN PATIENTS WITH MULTIPLE SCLEROSIS IN ARGENTINA.

Author

ROJAS, JUAN I., ALONSO, RICARDO, CABRERA, MARIELA, CONTENTTI, EDGAR CARNERO, CRISTIANO, EDGARDO, DERI, NORMA, HRYB, JAVIER, LOPEZ, PABLO, LUETIC, GERALDINE, PATRUCCO, LILIANA, TKACHUK, VERONICA, YSRRAELIT, MARÍA C., ZANGA, GISELA, CRUCES, LEONEL, TURK, GABRIELA, LONGUEIRA, YESICA, LAUFER, NATALIA, and NUÑEZ, SEBASTIAN

Abstract

Introduction: The objective was to assess the immunogenicity and effectiveness of vaccines against SARSCoV-2 in multiple sclerosis (MS) patients included in the Argentinean MS registry. Methods: A prospective cohort study between May and December 2021. The primary outcome was immunogenicity and effectiveness of vaccines during a three-month follow-up. Immunogenicity was evaluated based on detection of total antibodies (Ab) against spike protein and neutralizing Ab in serum 4 weeks after the second vaccine dose. A positive COVID-19 case was defined according to Argentinean Ministry of Health. Results: 94 patients were included, mean age: 41.7 ± 12.1 years. Eighty (85.1%) had relapsing remitting multiple sclerosis (RRMS); 30 (31.9%) were under fingolimod treatment. The Sputnik V vaccine was the first dose in 33 (35.1%), and AstraZeneca in 61 (64.9%). In 60 (63.8%), the vaccine elicited a specific humoral response. Immunological response according to the vaccination schemes showed no qualitative differences (p = 0.45). Stratified analysis according to the MS treatment showed that a significantly smaller number of subjects developed antibodies against spike antigen among those that were on ocrelizumab compared to other groups (p ≤ 0.001), while a reduced number of patients under ocrelizumab where evaluated (n = 7). This was also observed for neutralizing antibodies in the ocrelizumab group (p < 0.001). During the three-month follow-up, two individuals were diagnosed with COVID-19. Conclusion: We found that MS patients that received Sputnik V or AstraZeneca vaccines for SARS-CoV-2 developed a serological response with no differences between the vaccines used. [ABSTRACT FROM AUTHOR]

Published
2023

41. Myelin-associated glycoprotein activation triggers glutamate uptake by oligodendrocytes in vitro and contributes to ameliorate glutamate-mediated toxicity in vivo

Author

Vivinetto, Ana L., primary, Castañares, Clara, additional, Garcia-Keller, Constanza, additional, Moyano, Ana Lis, additional, Falcon, Cristian, additional, Palandri, Anabela, additional, Rozés-Salvador, Victoria, additional, Rojas, Juan I., additional, Patrucco, Liliana, additional, Monferran, Clara, additional, Cancela, Liliana, additional, Cristiano, Edgardo, additional, Schnaar, Ronald L., additional, and Lopez, Pablo H.H., additional

Published
2022
Full Text
View/download PDF

42. Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina

Author

Carnero Contentti, Edgar, primary, Lopez, Pablo A., additional, Pettinicchi, Juan Pablo, additional, Criniti, Juan, additional, Pappolla, Agustín, additional, Miguez, Jimena, additional, Patrucco, Liliana, additional, Cristiano, Edgardo, additional, Liwacki, Susana, additional, Tkachuk, Verónica, additional, Balbuena, María E., additional, Vrech, Carlos, additional, Deri, Norma, additional, Correale, Jorge, additional, Marrodan, Mariano, additional, Ysrraelit, María C., additional, Leguizamon, Felisa, additional, Luetic, Geraldine, additional, Menichini, María L., additional, Tavolini, Darío, additional, Mainella, Carolina, additional, Zanga, Gisela, additional, Burgos, Marcos, additional, Hryb, Javier, additional, Barboza, Andrés, additional, Lazaro, Luciana, additional, Alonso, Ricardo, additional, Fernández Liguori, Nora, additional, Nadur, Débora, additional, Chercoff, Aníbal, additional, Alonso Serena, Marina, additional, Caride, Alejandro, additional, Paul, Friedemann, additional, and Rojas, Juan I., additional

Published
2022
Full Text
View/download PDF

45. The Multiple Sclerosis Data Alliance Catalogue

Author

Geys, Lotte, primary, Parciak, Tina, additional, Pirmani, Ashkan, additional, McBurney, Robert, additional, Schmidt, Hollie, additional, Malbaša, Tanja, additional, Ziemssen, Tjalf, additional, Bergmann, Arnfin, additional, Rojas, Juan I., additional, Cristiano, Edgardo, additional, García-Merino, Juan Antonio, additional, Fernández, Óscar, additional, Kuhle, Jens, additional, Gobbi, Claudio, additional, Delmas, Amber, additional, Simpson-Yap, Steve, additional, Nag, Nupur, additional, Yamout, Bassem, additional, Steinemann, Nina, additional, Seeldrayers, Pierrette, additional, Dubois, Bénédicte, additional, van der Mei, Ingrid, additional, Stahmann, Alexander, additional, Drulovic, Jelena, additional, Pekmezovic, Tatjana, additional, Brola, Waldemar, additional, Tintore, Mar, additional, Kalkers, Nynke, additional, Ivanov, Rumen, additional, Zakaria, Magd, additional, Naseer, Maged Abdel, additional, Van Hecke, Wim, additional, Grigoriadis, Nikolaos, additional, Boziki, Marina, additional, Carra, Adriana, additional, Pawlak, Mikolaj A., additional, Dobson, Ruth, additional, Hellwig, Kerstin, additional, Gallagher, Arlene, additional, Leocani, Letizia, additional, Dalla Costa, Gloria, additional, de Carvalho Sousa, Nise Alessandra, additional, Van Wijmeersch, Bart, additional, and Peeters, Liesbet M., additional

Published
2021
Full Text
View/download PDF

46. Clinical and demographic characteristics of male MS patients included in the national registry –RelevarEM. Does sex or phenotype make the difference in the association with poor prognosis?

Author

Luetic, Geraldine G., primary, Menichini, María Laura, additional, Vrech, Carlos, additional, Pappolla, Agustín, additional, Patrucco, Liliana, additional, Cristiano, Edgardo, additional, Marrodán, Mariano, additional, Ysrraelit, María C., additional, Fiol, Marcela, additional, Correale, Jorge, additional, Cohen, Leila, additional, Alonso, Ricardo, additional, Silva, Berenice, additional, Casas, Magdalena, additional, Garcea, Orlando, additional, Deri, Norma, additional, Burgos, Marcos, additional, Liwacki, Susana, additional, Tkachuk, Verónica, additional, Barboza, Andrés, additional, Piedrabuena, Raúl, additional, Blaya, Patricio, additional, Steinberg, Judith, additional, Martínez, Alejandra, additional, Carrá, Adriana, additional, Tavolini, Darío, additional, López, Pablo, additional, Knorre, Eduardo, additional, Nofal, Pedro, additional, Volman, Gabriel, additional, Contentti, Edgar Carnero, additional, Pinheiro, Amelia Alves, additional, Leguizamon, Felisa, additional, Silva, Emanuel, additional, Hryb, Javier, additional, Balbuena, María Eugenia, additional, Zanga, Gisela, additional, Kohler, Matías, additional, Chertcoff, Aníbal, additional, Lazaro, Luciana, additional, Tizio, Santiago, additional, Mainela, Carolina, additional, Reich, Edgardo, additional, Recchia, Luciano, additional, Blanche, Jorge, additional, Marcilla, Marcela Parada, additional, Fracaro, María Eugenia, additional, Sgrilli, Gustavo, additional, Divi, Pablo, additional, Jacobo, Miguel, additional, Cabrera, Mariela, additional, Cassara, Fátima Pagani, additional, Sinay, Vladimiro, additional, Curbelo, Celeste, additional, Míguez, Jimena, additional, Coppola, Mariano, additional, Liguori, Nora Fernández, additional, Martos, Iván, additional, Pettinicchi, Juan Pablo, additional, Viglione, Juan Pablo, additional, José, Gustavo, additional, Bestoso, Santiago, additional, Manzi, Rubén, additional, Vázquez, Guido, additional, Nadur, Débora, additional, Martínez, Carlos, additional, Serena, Marina Alonso, additional, and Rojas, Juan I., additional

Published
2021
Full Text
View/download PDF

47. Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM

Author

Rojas, Juan I., primary, Pappolla, Agustín, additional, Blaya, Patricio, additional, Marrodán, Mariano, additional, Ysrraelit, María C., additional, Luetic, Geraldine, additional, Liwacki, Susana, additional, Barboza, Andrés, additional, Burgos, Marcos, additional, Cohen, Leila, additional, Mainella, Carolina, additional, Zanga, Gisela, additional, Menichini, María L., additional, Tavolini, Dario, additional, Tkachuk, Verónica, additional, Lopez, Pablo, additional, Lequizamon, Felisa, additional, Knorre, Eduardo, additional, Nofal, Pedro, additional, Patrucco, Liliana, additional, Miguez, Jimena, additional, Cristiano, Edgardo, additional, Fiol, Marcela, additional, Correale, Jorge, additional, Gaitán, María I., additional, Alonso, Ricardo, additional, Silva, Berenice, additional, Garcea, Orlando, additional, Carrá, Adriana, additional, Fernandez Liguori, Nora, additional, Alonso Serena, Marina, additional, and Carnero Contentti, Edgar, additional

Published
2021
Full Text
View/download PDF

48. Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care

Author

Rojas, Juan I., primary, Carnero Contentti, Edgar, additional, Abad, Patricio, additional, Aguayo, Adriana, additional, Alonso, Ricardo, additional, Bauer, Johana, additional, Becker, Jefferson, additional, Bustos, Andrea K., additional, Carcamo, Claudia A., additional, Carra, Adriana, additional, Correa Diaz, Edgard P., additional, Correale, Jorge, additional, Cristiano, Edgardo, additional, Diaz, Alejandro J., additional, Fernandez Liguori, Nora, additional, Flores, Jose, additional, Fruns, Manuel, additional, Garcea, Orlando, additional, Giachello, Susana M., additional, Godoy, Melisa D., additional, Gracia, Fernando, additional, Hamuy, Victor F., additional, Henestroza, Paula R., additional, Navarra, Javier A., additional, Navas, Carlos, additional, Patrucco, Liliana, additional, Perez Bruno, Magdalena, additional, Prato, Andrea S., additional, Rivera, Victor M., additional, Rosa Martinez, Alma R., additional, Vanotti, Sandra, additional, Vazquez, Macarena, additional, Vizcarra, Darwin, additional, Ysrraelit, Maria C., additional, and Alonso Serena, Marina, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results